Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Frauke Muecksch, Yiska Weisblum, Christopher O. Barnes, Fabian Schmidt, Dennis Schaefer-Babajew, Zijun Wang, Julio C. C. Lorenzi, Andrew I. Flyak, Andrew T. DeLaitsch, Kathryn E. Huey‐Tubman, Shurong Hou, Celia A. Schiffer, Christian Gaebler, Justin Da Silva, Daniel Poston, Shlomo Finkin, Alice Cho, Melissa Cipolla, Thiago Y. Oliveira, Katrina G. Millard, Víctor Ramos, Anna Gazumyan, Magdalena Rutkowska, Marina Caskey, Michel C. Nussenzweig, Pamela J. Björkman, Théodora Hatziioannou, Paul D. Bieniasz
Topics & Concepts
BiologyNeutralizationAntibodyAffinity maturationVirologyPotencyAntigenHeterologousGerminal centerNeutralizing antibodyImmunologyCoronavirusGeneticsCoronavirus disease 2019 (COVID-19)B cellGeneIn vitroDiseaseInfectious disease (medical specialty)MedicinePathologySARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyCRISPR and Genetic Engineering